(Q37286716)

19 August 2017

1 reference

title

Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

Dipshikha Chakravortty

series ordinal

3

object named as

Dipshikha Chakravortty

1 reference

19 August 2017

1

Amit Lahiri

1 reference

19 August 2017

Priyanka Das

2

1 reference

PubMed ID

18835576

19 August 2017

language of work or name

English

0 references

publication date

7 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

26

1 reference

19 August 2017

6777-6783

1 reference

19 August 2017

52

1 reference

Vaccinology: past achievements, present roadblocks and future promises

19 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Memory T cells and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Design and selection of vaccine adjuvants: animal models and human trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligodeoxynucleotides as vaccine adjuvants in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Adjuvant activity of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Triggering TLR signaling in vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Phagocytosis and innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Coupling Toll-like receptor signaling with phagocytosis: potentiation of antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Regulation of phagosome maturation by signals from toll-like receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Phagosome maturation proceeds independently of stimulation of toll-like receptors 2 and 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

TLR11 activation of dendritic cells by a protozoan profilin-like protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Implication of CpG-ODN and reactive oxygen species in the inhibition of intracellular growth of Salmonella typhimurium in hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

CpG-DNA aided cross-priming by cross-presenting B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor 3 promotes cross-priming to virus-infected cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor ligands directly promote activated CD4+ T cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Recognition of lipopeptides by Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The Lyme disease vaccine takes its toll

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The immunobiology of the TLR9 subfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Therapeutic potential of Toll-like receptor 9 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Toll or toll-free adjuvant path toward the optimal vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Nod-like proteins in immunity, inflammation and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

NOD-like receptors (NLRs): bona fide intracellular microbial sensors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The cytosolic pattern recognition receptor NOD1 induces inflammatory interleukin-8 during Chlamydia trachomatis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Cytosolic detection of flagellin: a deadly twist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.045

10.1016/J.VACCINE.2008.09.045

7 January 2021

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18835576